

Electronic Acknowledgement Receipt

EFS ID:	9966787
Application Number:	10779439
International Application Number:	
Confirmation Number:	8764
Title of Invention:	NITROGEN-SUBSTITUTED HEXAHYDROPYRAZINO[1,2-A]PYRIMIDINE-4,7-DIONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS
First Named Inventor/Applicant Name:	Stefanie Flohr
Customer Number:	05487
Filer:	Serena I. Farquharson/Maribel Mendez
Filer Authorized By:	Serena I. Farquharson
Attorney Docket Number:	DEAV2003/0072 US NP
Receipt Date:	27-APR-2011
Filing Date:	13-FEB-2004
Time Stamp:	14:54:16
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$ 100
RAM confirmation Number	1205
Deposit Account	181982
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Miscellaneous Incoming Letter	DEAV2003-0072USNPCOT4-27-2011.pdf	118444 c4b3d2ea7534d38f2d465e3d0cc6e93980b08b76	no	1

Warnings:

Information:

2	Request for Certificate of Correction	DEAV2003-0072USCNTCCRE4-27-2011.pdf	101676 94ad1cf4a787be1a49ddb3c989f3f1eda62cc4ec	no	3
---	---------------------------------------	-------------------------------------	--	----	---

Warnings:

Information:

3	Request for Certificate of Correction	DEAV2003-0072USNPCOC4-26-2011.pdf	100441 cad1cc068bbe906f11482f9d1f4fb3173e485251	no	3
---	---------------------------------------	-----------------------------------	--	----	---

Warnings:

Information:

4	Fee Worksheet (PTO-875)	fee-info.pdf	30542 468e120319607d0fb0c1bbc78767a7981e5c1e6	no	2
---	-------------------------	--------------	--	----	---

Warnings:

Information:

Total Files Size (in bytes):	351103
-------------------------------------	--------

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.